Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1633 1651 1699
This examiner grants 56% of resolved cases
Evelyn Y. Pyla is an examiner in Tech Center 1600 and Art Unit 1600. She has handled 562 resolved cases with an allowance rate of 55.7 percent. This 55.7 percent rate indicates a balanced approach to examination, providing a baseline for applicant expectations.
The interview lift is 47.1 percent. This figure suggests that conducting an interview is a highly effective strategy for increasing the likelihood of a grant. The 47.1 percent lift provides a substantial boost to the allowance rate, making it a critical tactic for practitioners to consider.
The median days to allowance is 1323. This timeline represents the typical duration for applications to reach a final grant. With 562 resolved cases, these metrics offer a clear view of the examiner's performance. The 1323-day median defines the expected prosecution experience for applicants in this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18478904 | METHOD FOR PREPARING SOLVENT-FREE 3D BIOLOGICAL BILAYER MEMBRANE STRUCTURE IN PHYSIOLOGICAL SOLUTION AND 3D BIOLOGICAL BILAYER MEMBRANE STRUCTURE USING THE SAME | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17762396 | CELL CULTURING MATERIALS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18771037 | SYSTEM AND METHOD FOR CELL LEVITATION AND MONITORING | Non-Final OA | BETH ISRAEL DEACONESS MEDICAL CENTER |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18543705 | Regeneration of a Functional Pulmonary Vascular Bed | Final Rejection | The General Hospital Corporation |
| 18052600 | RESPIRATORY SYNCTIAL VIRUS RNA VACCINE | Non-Final OA | SANOFI |
| 18622525 | COMPOSITIONS AND METHODS FOR REDUCED TOXICITY IN TRANSPLANTATION USING JANUS KINASE (JAK) INHIBITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18804707 | METHOD OF TREATMENT | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | Non-Final OA | Fred Hutchinson Cancer Center |
| 18582703 | 3D spheroid having uniform size and composition comprising neuron and astrocyte derived from Alzheimer's disease patients, method for producing thereof, and method and kit for screening drug using thereof | Non-Final OA | Industry-University Cooperation Foundation Hanyang University Erica Campus |
| 18287710 | Reprogramming Somatic Cells on Microcarriers | Final Rejection | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 18290396 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | Non-Final OA | THE U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 17997351 | TAGGED GENE EDITING TECHNOLOGY FOR CLINICAL CELL SORTING AND ENRICHMENT | Non-Final OA | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy